TELOMERASE INHIBITOR COMPOUNDS
Provided are telomerase inhibitor compounds. Some compounds include a lactone or lactam group that is covalently bonded to a phenyl ring, which is itself bonded to a pyrazole group. In other cases, a sulfonamide-containing moiety is covalently bonded to a phenyl ring, which is itself bonded to a pyrazole group. In some embodiments, the telomerase inhibitor compound has a vinyl sulfonamide group bonded to an amide moiety and an aromatic group. In other cases, the inhibitor compound has an isothiazolidine 1,1-dioxide core that is bonded to a phenyl group. Aspects of the invention also include pharmaceutical compositions comprising the subject telomerase inhibitor compounds, as well as methods of treating telomerase-related diseases or conditions.
1 . A compound of formula (I):
wherein:
X is O or NR X ;
R X is selected from the group consisting of H, D, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carbonyl, carboxy, and substituted versions thereof;
each R 1 and R 2 is independently selected from the group consisting of H, D, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, thiol, thioether, and substituted versions thereof;
R 9 is H, D, or alkyl; and
A is a 5- or 6-membered aromatic ring that is optionally substituted or a heterocyclic ring that is optionally substituted.
2 . The compound of claim 1 , wherein X is O.
3 . The compound of claim 1 , wherein X is NR X .
4 . The compound of claim 1 , wherein the compound has formula (Ia-A):
wherein:
m is 0 or an integer from 1 to 5; and
each R 3 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof, provided that two adjacent R 3 groups along with the atoms to which they are attached can form a cyclic ring.
5 . The compound of claim 1 , wherein the compound has formula (Ib-A)
wherein:
n is 0 or an integer from 1 to 4; and
E is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof.
6 . The compound of claim 5 , wherein E is selected from the group consisting of alkyl, aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, heterocyclyl, and substituted versions thereof.
7 . The compound of claim 6 , wherein E is a 5-membered heteroaryl or substituted heteroaryl group.
8 . The compound of claim 7 , wherein E is pyrazole or substituted pyrazole.
9 . The compound of claim 8 , wherein the compound has formula (Ib-1-A):
wherein:
R 4 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carbonyl, carboxy, and substituted versions thereof;
z is 0, 1, or 2; and
each R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof.
10 . The compound of claim 7 , wherein E is selected from the group consisting of triazole, substituted triazole, 6-membered aryl, 6-membered substituted aryl, 6-membered heteroaryl, and 6-membered substituted heteroaryl.
11 . The compound of claim 1 , wherein the compound has formula (Ic-A):
wherein:
p is 0 or an integer ranging from 1 to 4; and
G is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof.
12 . The compound of claim 11 , wherein G is selected from the group consisting of alkyl, aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, heterocyclyl, and substituted versions thereof.
13 . The compound of claim 1 , wherein the compound has formula (Id-A):
wherein:
q is 0 or an integer from 1 to 3; and
ring B is a 5- or 6-membered aryl or heteroaryl ring.
14 . The compound of claim 13 , wherein ring B is heteroaryl.
15 . The compound of claim 14 , wherein ring B is pyridine, pyrrole, imidazole, or pyrrolidine.
16 . The compound of claim 1 , wherein the compound has a structure selected from the group consisting of:
5-(2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-methylenedihydrofuran-2 (3H)-one
5-(4-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-methylenedihydrofuran-2 (3H)-one
5-(4-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-1-methyl-3-methylenepyrrolidin-2-one
5-(2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)phenyl)-3-methylenedihydrofuran-2 (3H)-one
3-(1-methyl-1H-pyrazol-4-yl)-4-(4-methylene-5-oxotetrahydrofuran-2-yl)benzoic acid
4-(1-methyl-1H-pyrazol-4-yl)-3-(4-methylene-5-oxotetrahydrofuran-2-yl)benzoic acid
N-methyl-2-(4-(2-(4-methylene-5-oxotetrahydrofuran-2-yl)phenyl)-1H-pyrazol-1-yl)acetamide
5-(2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-methylenepyrrolidin-2-one
5-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-methylenepyrrolidin-2-one
5-(5-chloro-2-(1H-pyrazol-4-yl)phenyl)-3-methylenedihydrofuran-2 (3H)-one
5-(5-fluoro-2-(1H-pyrazol-4-yl)phenyl)-3-methylenedihydrofuran-2 (3H)-one
5-(4-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-5-methyl-3-methylenedihydrofuran-2 (3H)-one
(E)-5-(4-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-(2-fluorobenzylidene)dihydrofuran-2 (3H)-one
5-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-1-methyl-3-methylenepyrrolidin-2-one
5-(3-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-1-methyl-3-methylenepyrrolidin-2-one
5-(4-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-1-methyl-3-methylenepyrrolidin-2-one
5-(4-fluoro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-methylenepyrrolidin-2-one
5-(4-fluoro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-1-methyl-3-methylenepyrrolidin-2-one
5-(5-fluoro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-1-methyl-3-methylenepyrrolidin-2-one
5-(4,5-difluoro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-methylenepyrrolidin-2-one
5-(4-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-3-methylenedihydrofuran-2 (3H)-one
5-(4-chloro-2-(1H-pyrazol-4-yl)phenyl)-4-methyl-3-methylenedihydrofuran-2 (3H)-one
5-(4,5-dichloro-2-(1-methyl-1H-pyrrol-3-yl)phenyl)-4-methyl-3-methylenedihydrofuran-2 (3H)-one
5-(4-chloro-2-(1H-pyrazol-4-yl)phenyl)-3-methylenedihydrofuran-2 (3H)-one
5-(4-fluoro-2-(1H-pyrazol-4-yl)phenyl)-3-methylenedihydrofuran-2 (3H)-one, and
5-(4,5-dichloro-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-methyl-3-methylenedihydrofuran-2 (3H)-one.
17 . A compound of formula (II):
wherein:
n is 0, 1, 2, or 3;
each R 1 , R 2 , R 6 , R 7 , and R 9 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof; and
each R 3 , R 4 , R 5 , and R 8 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carbonyl, carboxy, and substituted versions thereof.
18 .- 27 . (canceled)
28 . A compound of formula (III):
wherein:
n is 0 or an integer ranging from 1 to 4;
each R 1 , R 4 , and R 5 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof;
R 2 is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
R 3 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carbonyl, carboxy, and substituted versions thereof.
29 .- 36 . (canceled)
37 . A compound of formula (IV):
wherein:
R 1 and R 2 are each independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, and substituted versions thereof, provided that at least one of R 1 and R 2 is aryl, heteroaryl, or a substituted version thereof;
L 1 and L 2 are each independently absent or an alkylene group;
R 3 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, and substituted versions thereof; and
R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof.
38 .- 53 . (canceled)
54 . A compound of formula (V):
wherein:
R 1 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carbonyl, carboxy, and substituted versions thereof;
each R 2 and R 3 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof; and
n is 0 or an integer from 1 to 4.
55 .- 59 . (canceled)
60 . A compound of formula (VI):
wherein:
n is 0, 1, 2, or 3;
each R 1 , R 2 , R 3 , R 5 , R 6 , and R 8 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof; and
R 4 and R 7 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carbonyl, carboxy, and substituted versions thereof.
61 .- 67 . (canceled)
68 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
69 . The pharmaceutical composition of claim 68 , further comprising a second compound.
70 . (canceled)
71 . A method of treating a patient for a telomerase-related condition, the method comprising:
administering a pharmaceutical composition of claim 68 to the patient.
72 . (canceled)
73 . The method of claim 71 , wherein the telomerase-related condition is a cancer.
74 . The method of claim 73 , wherein the cancer is a hematological malignancy.
75 . The method of claim 73 , wherein the cancer is selected from the group consisting of acute and chronic leukemias, lymphomas, multiple myeloma and myelodysplastic syndromes, myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), polycythemia vera (PV), Chronic Myelogenous Leukemia (CML), myelofibrosis (MF), acute myelogenous leukemia (AML), and myelodysplastic syndromes (MDS).
76 . A method of treating a patient for a telomerase-related condition, the method comprising:
administering a compound of claim 1 to the patient.
77 . (canceled)
78 . The method of claim 76 , wherein the telomerase-related condition is a cancer.
79 . The method of claim 78 , wherein the cancer is a hematological malignancy.
80 . The method of claim 79 , wherein the cancer is selected from the group consisting of acute and chronic leukemias, lymphomas, multiple myeloma and myelodysplastic syndromes, myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), polycythemia vera (PV), Chronic Myelogenous Leukemia (CML), myelofibrosis (MF), acute myelogenous leukemia (AML), and myelodysplastic syndromes (MDS).